Bod Science and Malaysian investment firm Antah Group have signed a non-binding Letter of Intent to identify, develop and commercialise medicinal cannabis products in Malaysia.
Bod’s products and delivery platforms will be used in clinical trials, while Antah will have exclusive use of the trial product for sales and distribution in Malaysia. Potential need states include autism spectrum disorder, anxiety and depression.
The two firms said the agreement will give them first-mover advantage when a regulated medicinal cannabis market is established in Malaysia. The country is still awaiting its first clinical trial involving the medicine.
Bod said neighbouring Thailand’s legal cannabis market is expected to reach US$9.6 billion by 2030, growth largely attributed to rising medicinal use.
CEO Jo Patterson added the collaboration provides Bod with a “value-driving opportunity to be at the forefront of exploration into the use of medical cannabis in the Malaysian healthcare industry alongside one of the country’s largest companies”.
She added: “Bod’s unique delivery platforms, and patented products, will have a first-mover advantage via Antah’s exclusive rights for sales and distribution in the Malaysian market.”
Antah has interests in industries including healthcare, power generation, and property development.
